oa Molecular Diagnosis and Vaccines - Expression of apoptotic inhibitors Survivin and Aven in adult acute myeloid leukemia

Volume 4, Issue 1
  • ISSN : 1687-2010



Survivin, and Aven are members of the inhibitor of apoptosis (IAP) proteins family. They are reported to be over-expressed in many cancers including leukemia. Previous studies suggested that Survivin is implicated in both control of apoptosis and regulation of cell division. The aim of this study was to examine the expression of the two apoptotic inhibitors - Survivin and Aven-at the messenger (m)RNA level in acute myeloid leukemias (AML) in relation to the clinical and hematological findings. Thirty adult patients with acute myeloid leukemia (AML) and 10 healthy subjects were studied. Patients were subjected to complete blood picture, bone marrow examination and immunophenotyping. Based on the French American British classification, they were subdivided to M1, M2, M3, M4 and M5. A reverse transcriptase-polymerase chain reaction (RTPCR) was used to investigate the expression of Survivin, and Aven mRNA. The AML patients showed expression of Survivin (206 bp) but not Aven mRNA. In contrast, neither Survivin nor Aven were expressed in the control group. Out of the 30 patients, 23 patients (76.6 %) showed detectable levels of Survivin expression (p<0.001). Quantitative analysis revealed differences in expression levels of Survivin mRNA between different FAB subtypes. Three subtypes (M1, M4 and M5) showed a slightly higher expression level of Survivin mRNA (mean values of 0.56, 0.57 and 0.81 respectively) than the other two subgroups (M2 and M3) (mean range 0.04 and 0.1 respectively). A significant correlation was found between Survivin expression level and peripheral blood (PB) blast % in M5 subtype (p=0.02). It is concluded that, Survivin is an important antiapoptotic signal in acute myeloid leukemia. Up-regulation of Survivin expression in AML may be involved in its pathogenesis and may provide a useful tool for prognosis.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error